ReviewBlood2016
Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.
Review in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07682662 (Evaluation of a Standardized Low-Dose Bolus Ketamine Pathway for Management of Pediatric Sickle Cell Patients Presenting to the Emergency Department With Pain), which is not on this map. Cited by 235 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of a Standardized Low-Dose Bolus Ketamine Pathway for Management of Pediatric Sickle Cell Patients Presenting to the Emergency Department With Pain
Who cites it
235 citing papers in PubMed, 3 syntheses or guidelines pooled it, 391 citations in OpenAlex.
- Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis.PloS one · 2024Pooled it
- Safety of maximal cardiopulmonary exercise testing in individuals with sickle cell disease: a systematic review.British journal of sports medicine · 2022Pooled it
- Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.BMJ open · 2020Pooled it
- Trial
- Trial
- Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study.American journal of hematology · 2020Trial
- High levels of proinflammatory cytokines IL-6 and IL-8 are associated with a poor clinical outcome in sickle cell anemia.Annals of hematology · 2020Trial
- Phase 2 trial of montelukast for prevention of pain in sickle cell disease.Blood advances · 2020Trial
- Association Between Nitric Oxide, Oxidative Stress, Eryptosis, Red Blood Cell Microparticles, and Vascular Function in Sickle Cell Anemia.Frontiers in immunology · 2020Trial
- PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study.Clinical and translational science · 2019Trial
- Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease.PloS one · 2019Trial
- A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study.American journal of hematology · 2018Trial
- Platelets in sickle cell disease: biomarkers, mediators, and lessons from clinical trials.Blood vessels, thrombosis & hemostasis · 2026Review
- Identification of Clinical Sub-Phenotypes of Sickle Cell Disease Using Latent Class Analysis.American journal of hematology · 2026Article
- Activation of Platelet Caspase-1 and P-Selectin Over-Expression in Sickle Cell Disease Patients: An Involvement of NLRP3 Inflammasome?Journal of cellular and molecular medicine · 2026Article
- Emerging preclinical evidence supports a potential role for cannabidiol in the management of sickle cell disease.Haematologica · 2026Review
- Sickle red blood cell/Siglec-9 interactions contribute to neutrophil activation in SCD and are associated with survival.Blood. Red cells & iron · 2026Article
- Adaptive Immune Remodeling in Sickle Cell Disease: Linking Hemolysis-Driven Inflammation to Immune Dysfunction.Experimental hematology · 2026Review
- Estimated glomerular filtration rate discordance and cardiopulmonary morbidity in sickle cell disease.Blood advances · 2026Article
- Should Sickle Cell Disease Be Considered a Cancer Predisposition Syndrome?Children (Basel, Switzerland) · 2026Review
175 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Sickle cell disease (SCD) is a severe genetic blood disorder characterized by hemolytic anemia, episodic vaso-occlusion, and progressive organ damage. Current management of the disease remains symptomatic or preventative. Specific treatment targeting major complications such as vaso-occlusion is still lacking. Recent studies have identified various cellular and molecular factors that contribute to the pathophysiology of SCD. Here, we review the role of these elements and discuss the opportunities for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.